title: Can virus therapy of human cancer be improved by apoptosis induction?
abstract: Direct virus inoculations and viral oncolysates may induce temporary remissions and prolong life with reduced tumor burden, or decrease relapse rates but fall short of curing human cancers. We propose: (i) investigations of Cassel's 73-T, an Ehrlich's mouse ascites carcinoma-adapted Newcastle disease virus (NDV) strain that so effectively reduced relapse rates in malignant melanoma if it is an admixture or a recombinant with a murine parvovirus; (ii) transfection of prostatic carcinoma cells with the TRMP gene; (iii) transfection of sarcoma cells with the fas gene followed by treatment with anti-fas monoclonal antibodies, and (iv) treatment of metastatic tumors with a parvovirus incorporating the apoptosis-inducer Ad5 E1A gene.Thus, replicating virions and haphazard generation of cytokines in the inoculated host could be replaced with transfection of single genes of well-defined, limited but selected efficacy.
authors.affiliation: St Joseph's Hospital, Department of Medicine, University of South Florida College of Medicine, Tampa 33677-4227, USA.
authors.forename: J G
authors.initials: JG
authors.lastname: Sinkovics
authors.forename: J
authors.initials: J
authors.lastname: Horvath
mesh_terms: D017500:Adenovirus E1A Proteins / Q000235:genetics; D000260:Adenoviruses, Human / Q000235:genetics; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D017209:Apoptosis; D005814:Genes, Viral; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D008545:Melanoma / Q000628:therapy; D051379:Mice; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000150:complications / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy*; D009857:Oncogenes; D017992:Parvovirus / Q000276:immunology; D011471:Prostatic Neoplasms; D012509:Sarcoma; D014162:Transfection; D014407:Tumor Cells, Cultured; D014614:Vaccines, Synthetic / Q000627:therapeutic use; D014765:Viral Vaccines / Q000627:therapeutic use*; D014777:Virus Diseases / Q000150:complications; D019014:fas Receptor / Q000096:biosynthesis / Q000276:immunology
chemical_list: D017500:Adenovirus E1A Proteins; D000911:Antibodies, Monoclonal; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D019014:fas Receptor